Jefferies Cuts PT on AVEO Pharmaceuticals (AVEO); More Cautious on Tivo Approval

February 14, 2013 12:45 PM EST
Get Alerts AVEO Hot Sheet
Price: $0.65 --0%

Rating Summary:
    3 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade AVEO Now!
Join SI Premium – FREE
Jefferies lowered its price target on AVEO Pharmaceuticals (NASDAQ: AVEO) from $9 to $6 following the Q4 update. The firm maintained a Hold rating.

The firm comments, "AVEO shared new details of the final overall survival (OS) analysis for tivozanib from its Phase 3 first-line kidney cancer study. We are incrementally more cautious following these data, particularly new subgroup analyses of the OS data, which we thought would be supportive but are instead mixed. We remain concerned about both the regulatory and commercial prospects for tivo."

For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.

Shares of AVEO Pharmaceuticals closed at $7.35 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment